Some results obtained in cancer tissues originating from the digestive system suggest that G6PD can counteract the programmed cellular death, as demonstrated by the lower expression of apoptotic markers Bcl-2 and Bcl-xL [46]. The gene discussed is BCL2; the disease is cancer.